Additional file 1 of Development and validation of prognostic nomograms based on De Ritis ratio and clinicopathological features for patients with stage II/III colorectal cancer

Additional file 1: Supplementary Figure 1. X-tile analyses of overall survival in thetraining set. Supplementary Figure 2. Kaplan-Meier curves and log-rank testing of overall survival in relation tolactate dehydrogenase (A), alkaline phosphatase (B), APRI (C), ALRI (D), ANRI(E), and APPRI (F) in the training set. SupplementaryFigure 3. Kaplan-Meier curves and log-rank testing of disease-free survivalin relation to lactate dehydrogenase (A), alkaline phosphatase (B), APRI (C),ALRI (D), ANRI (E), and APPRI (F) in the training set. Supplementary Figure 4. Kaplan-Meier curves and log-rank testing ofoverall survival in relation to lactate dehydrogenase (A), alkaline phosphatase(B), APRI (C), ALRI (D), ANRI (E), and APPRI (F) in the testing set. Supplementary Figure 5. Kaplan-Meiercurves and log-rank testing of disease-free survival in relation to lactatedehydrogenase (A), alkaline phosphatase (B), APRI (C), ALRI (D), ANRI (E), andAPPRI (F) in the testing set. SupplementaryFigure 6. Prognostic values of De Ritis ratio in different subgroups. Subgroupanalyses were performed in colorectal cancer patients stratified by age,gender, tumor location, tumor diameter, CEA, and CA19-9. All the analyses wereadjusted for the significant clinicopathological factors in relation to overallsurvival (A) and disease-free survival (B). Supplementary Table 1. Association between lactate dehydrogenase andclinicopathological features in the training set. Supplementary Table 2. Association between alkaline phosphatase andclinicopathological features in the training set. Supplementary Table 3. Association between De Ritis ratio andclinicopathological features in the training set. Supplementary Table 4. Association between APRI andclinicopathological features in the training set. Supplementary Table 5. Association between ALRI andclinicopathological features in the training set. Supplementary Table 6. Association between ANRI andclinicopathological features in the training set. Supplementary Table 7. Association between APPRI andclinicopathological features in the training set. Supplementary Table 8. The overall survival rates at 1-, 3-, and 5-year of patients stratified by serum liver enzyme markers in the training set. Supplementary Table 9. The disease-free survival rates at 1-, 3-, and 5-year of patients stratified by serum liver enzyme markers in the training set. Supplementary Table 10. The overall survival rates at 1-, 3-, and 5-year of patients stratified by serum liver enzyme markers in the testing set. Supplementary Table 11. The disease-free survival rates at 1-, 3-, and 5-year of patients stratified by serum liver enzyme markers in the testing set. Supplementary Table 12. The C-index of TNM staging, AJCC staging and nomograms. SupplementaryTable 13. Time-dependent ROC analyses for predicting overall survival and disease-free survival of patients with colorectal cancer in the training set. Supplementary Table 14. Time-dependent ROC analyses for predicting overall survival and disease-free survival of patients with colorectal cancer in the testing set.